Lakewood-amedex Biotherapeutics Inc. · NASDAQ:LABT
Lakewood-amedex Biotherapeutics — Investor Presentation (July 2026)
21 slides from Lakewood-amedex Biotherapeutics's investor presentation, Jul 15, 2026
Slide 1: Pioneering Bisphosphocin Compounds
Pioneering Bisphosphocin® Compounds Advancing a novel class of fast- acting antimicrobials toaddress the global threat ofresistance 1
Slide 2: Forward-looking Statements
Forward-looking Statements This presentation may contain forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Generally, the words "believe," "expect," "intends," "estimate," "anticipate," "project," "will" and similar expressions identify forward-looking st
Slide 3: Antimicrobial Resistance (AMR): A Global Public Health Threat
Antimicrobial Resistance (AMR): A Global Public Health Threat Directly causes 1.14 million deaths annually and contributes to nearly 4.7 million deaths worldwide(a) Unaddressed AMR could cost ~$3.8 trillion in lost global G D P by 2050(b) In the U.S., infections from six c o m m o n multidrug-resist
Slide 4: Value Proposition of Patented Bisphosphocin Class
Value Proposition of Patented Bisphosphocin ® Class First-in-class, antimicrobial compounds with potential to mitigate the impact of the global AMR crisis Broad-spectrum activity against both susceptible and clinically relevant resistant pathogens ( a) Demonstrated cidal activity against biofilm org
Slide 5: Bisphosphocin — Proposed Mechanism of Action
Bisphosphocin ® — Proposed Mechanism of Action • Targets bacteria through a pH- and concentration-dependent destabilization of the bacterial cell membrane, typically within one minute of exposure • Broad-spectrum antibacterial activity, including resistant strains (MRSA, VRE), with demonstrated effe
Slide 6: Lead Program: Infected Diabetic Foot Ulcer (iDFU)
Lead Program: Infected Diabetic Foot Ulcer (iDFU) 6 Global Prevalence • 830M people with diabetes;(a) about one third will develop a DFU ( b ) Infection Rate • ~50% of D FUs become infected; ma ny patients face recurrent events (b) Severe Ou tcomes • Infections are a critical risk factor for amputat
Slide 7: Nu-3 Selected for Clinical Development
Nu-3 Selected for Clinical Development ( a ) Broad spectrum in vitro; Nu-3 shown to be rapidly cidal against a broad spectrum of microbes, including resistant strains, with low potential for resistance development and activity against biofilm Robust efficacy in skin infection models; Nu-3 active as
Slide 8: Nu-3 demonstrates rapid bacterial kill in vitro
Nu-3 demonstrates rapid bacterial kill in vitro (a) In the absence of Nu-3 the bacteria are unaffected over the 20-minute time course. 25 m g Vehicle C ontrol At a low concentration (25 mg /ml - 2.5%), all the bacteria are killed within 10 minutes. 50 m g 100 m g At higher concentrations of Nu-3 (50
Slide 9: Nu-3 Gel Formulation Outperforms Solution Formulation
Nu-3 Gel Formulation Outperforms Solution Formulation(a) 1& 2 Hours At 1 and 2 hours post established infection both 10% gel and 10% solution of Nu-3 show >95% inhibition of MRSA growth 4 Hours At 4 hours post established infection the 10% gel outperforms the 10% solution of Nu-3 in blocking MRSA gr
Slide 10: Nu-3 Gel active either once or twice per day in multidose study
Nu-3 Gel active either once or twice per day in multidose study(a) 5% Gel After 5 days of treatment with 5% Nu-3 gel both once-a-day (QD) and twice-a-day (BID) MRSA growth is >95% inhibited 5% Gel + 5 days recovery After 5 days of treatment plus 5 days recovery with 5% Nu-3 gel the twice-a-day (BID)
Slide 11: Advantages of Bisphosphocin Class in Combating AMR
Advantages of Bisphosphocin ® Class in Com bat ing AMR: based on available non-clinical evidence 11 Right Drug Right Application Right MOA
Slide 12: Clinical Evidence Supporting Development of Nu-3
Clinical Evidence Supporting Development of Nu-3 • A 21‐Day Repeat Patch Test to Evaluate the Irritation Potential of Test Product (2% Nu‐3 in 0.85% Saline, W/V) on Abraded and Intact Skin Sites with Controls • 35 healthy subjects exposed • Abraded skin: Positive control > 2% Nu‐3 > Negative saline
Slide 13: Upcoming Phase 2a/2b Study Design with New Gel Formulation
Step One: Phase 2a Study SINGLE Blinded, R an d om ized Nu-3 gel 2% Nu-3 gel 5% Nu-3 gel 10% Active Treatment D ay 1 Day 14 Day 28 Follow u p N o treatment N o treatment N o treatment Step Two: Phase 2b Study 13 U p c o m i n g Phase 2a/2b Study Design with N e w Gel Formulation Indication • Infecte
Slide 14: iDFU Development and Regulatory Strategy
iDFU Development and Regulatory Strategy 14 Geographic Scope • Phase 2 U.S.development • Phase 3 International development Clinical Development • 2 small accessory studies full pharmacokinetic and skin sensitization • E n d of Phase 2 Meeting • Phase 3: In partnership to attain global reach and capa
Slide 15: Development Pipeline
N u -3 N u -8 N u -11 N u -10 Indication P rogram : Discovery Pre-clinical Phase 1 Phase 2 Phase 3 Status Targe ts: • Pulmonary Infections • Urinary Tract Infections • Oral Mucositis • Otitis Externa Skin and Soft tissue Infections (SSTI), e.g., Infected Diabetic Foot Ulcers (iDFU) Phase 2initiation
Slide 16: Upcoming Milestones
Upcoming Milestones 2Q26 • Drug product manufacturing initiated • Site enrollment initiated 16 3Q26 • Drug product manufacturing completed • Site enrollment completed • Clinical Trial Commences • First Patient First Visit 4Q26 • Clinical Trial Complete • Last Patient Last Visit 4Q26/1Q27 • Top Line
Slide 17: Robust Intellectual Property Portfolio
Robust Intellectual Property Portfolio 71 Issu ed 30 P e ndin g 101 Patents 17 Patent Exclusivity • Key filings provide protection through 2038 • Recent applications extend through 2044 Patent Coverage • Patents cover composition-of-matter of the Bisphosphocin ® class and other related classes of co
Slide 18: Nu-3 Well Positioned in Competitive Landscape
Nu-3 Well Positioned in Competitive Landscape 18 Only One Direct and Comparable Competitor – Recce's R327 • Topical agent for Skin & Soft Tissue Infections – focus on iDFU • Late-stage development in Australia & Indonesia • No approved topical for treatment of iDFU • No efficacy against resistant pa
Slide 19: Experienced Management with Industry Depth
Experienced Management with Industry Depth Kelvin Cooper, Ph.D. Chief Executive Officer • 45 Years in the Pharmaceutical Industry • 30 years at Pfizer • Executive Leadership roles in D r u g Discovery, D r u g Development, Manufacturing, and Commercial Peter C e c ca c c i Chief Financial Officer •
Slide 20: Pioneering Innovations to Combat Drug-Resistant Infections
Pioneering Innovations to Com bat Drug-Resistant Infections Clinical-stage biotechnology co m p a ny developing a novel class of fast-acting, broad-spectrum antimicrobials — Bisphosphocin ® comp ou n d s — to treat infectious diseases a n d reduce the threat posed by antibiotic-resistant microbes Ph
Slide 21: AQ ° eee,
“996 AQ ° eee, “Lakewood “2 AAMEdEX BIOTHERAPEUTICS
Lakewood-Amedex Biotherapeutics — Investor Presentation (July 2026) on 6ix